157 related articles for article (PubMed ID: 35052685)
1. Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model.
Su M; Cao D; Wang Z; Duan Y; Huang Y
Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052685
[TBL] [Abstract][Full Text] [Related]
2. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
3. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
4. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
6. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.
Nagaya T; Tanaka N; Kimura T; Kitabatake H; Fujimori N; Komatsu M; Horiuchi A; Yamaura T; Umemura T; Sano K; Gonzalez FJ; Aoyama T; Tanaka E
BBA Clin; 2015 Jun; 3():168-74. PubMed ID: 26674248
[TBL] [Abstract][Full Text] [Related]
9. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
10. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
[TBL] [Abstract][Full Text] [Related]
11. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
Park H; Liu Y; Kim HS; Shin JH
Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
[TBL] [Abstract][Full Text] [Related]
12. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
13. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
[TBL] [Abstract][Full Text] [Related]
14. Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis.
Shearn CT; Smathers RL; Jiang H; Orlicky DJ; Maclean KN; Petersen DR
J Nutr Biochem; 2013 Aug; 24(8):1436-45. PubMed ID: 23465594
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
Wu M; Singh SB; Wang J; Chung CC; Salituro G; Karanam BV; Lee SH; Powles M; Ellsworth KP; Lassman ME; Miller C; Myers RW; Tota MR; Zhang BB; Li C
Proc Natl Acad Sci U S A; 2011 Mar; 108(13):5378-83. PubMed ID: 21389266
[TBL] [Abstract][Full Text] [Related]
16. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
[TBL] [Abstract][Full Text] [Related]
17. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
18. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
19. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios.
Peter A; Cegan A; Wagner S; Lehmann R; Stefan N; Königsrainer A; Königsrainer I; Häring HU; Schleicher E
Clin Chem; 2009 Dec; 55(12):2113-20. PubMed ID: 19850634
[TBL] [Abstract][Full Text] [Related]
20. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]